Michael Gelband’s Summit Therapeutics SMMT Stock Holding History

Michael Gelband’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-256,255	Closed	-$4.86M	–	2024
2026 Q1	$4.86M	Buy	+256,255	New	+$4.14M	0.04%	449
2025 Q4	–	Sell	-23,513	Closed	-$486K	–	2032
2025 Q3	$486K	Buy	+23,513	New	+$570K	0.01%	1191
2023 Q3	–	Sell	-25,775	Closed	-$65K	–	2112
2023 Q2	$65K	Buy	+25,775	New	+$47K	﹤0.01%	1769
2021 Q2	–	Sell	-93,533	Closed	-$549K	–	2763
2021 Q1	$549K	Sell	93,533 -92,311	-50%	-$596K	0.01%	1279
2020 Q4	$873K	Buy	+185,844	New	+$787K	0.01%	931

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Michael Gelband's SMMT Position: Q2 2026 in Review

Michael Gelband sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 256,255 shares — an estimated $4.86M sold.

Michael Gelband first reported a position in SMMT in Q4 2020 and held it in 5 quarters. The position peaked at $4.86M in Q1 2026. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Michael Gelband reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 256,255 Summit Therapeutics shares in Q2 2026, an estimated $4.86M.
Michael Gelband first reported a position in Summit Therapeutics in Q4 2020 and held it in 5 quarters.
Michael Gelband's Summit Therapeutics position peaked at $4.86M in Q1 2026.
241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.